Zymeworks Inc.

ZYME

US98985Y1082

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
23.47 ^USD	-0.68%		+1.60%	-10.86%

23/12	Zymeworks Insider Sold Shares Worth $1,284,311, According to a Recent SEC Filing	MT
17/12	Truist Initiates Zymeworks at Buy With $40 Price Target	MT

Zymeworks Commences Strategic Initiative for Licensed Products to Enhance Future Cash Flows

Published on 11/18/2025 at 02:41 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Zymeworks Inc.

23/12	Zymeworks Insider Sold Shares Worth $1,284,311, According to a Recent SEC Filing	MT
17/12	Truist Initiates Zymeworks at Buy With $40 Price Target	MT
04/12	Zymeworks Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03:15 PM
21/11	B. Riley Raises Price Target on Zymeworks to $40 From $30, Keeps Buy Rating	MT
18/11	Zymeworks Inc. - Shareholder/Analyst Call
18/11	Zymeworks Inc. authorizes a Buyback Plan.	CI
18/11	Zymeworks Inc. announces an Equity Buyback for $125 million worth of its shares.	CI
18/11	Zymeworks Announces Board and Executive Changes	CI
18/11	Zymeworks Commences Strategic Initiative for Licensed Products to Enhance Future Cash Flows	MT
18/11	Zymeworks says authorizes $125 million share repurchase plan	RE
18/11	Top Midday Gainers	MT
17/11	Zymeworks Inc. Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera	CI
17/11	Traders Eye Delayed Jobs Report, Nvidia Earnings, Stifling US Equity Futures Pre-Bell	MT
17/11	Zymeworks' Phase 3 Trial for Gastroesophageal Cancer Treatment Shows Significant Improvement in Progression-Free Survival	MT
17/11	Top Premarket Gainers	MT
17/11	Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment	DJ
17/11	Zymeworks announces positive Herizon-GEA-01 phase 3 results supporting Ziihera as HER2-targeted agent-of-choice and new standard of care in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma	RE
07/11	Zymeworks Inc., Q3 2025 Earnings Call, Nov 06, 2025
07/11	Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on August 1, 2024.	CI
07/11	Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/11	Earnings Flash (ZYME) Zymeworks Inc. Reports Q3 Revenue $27.6M, vs. FactSet Est of $29.9M	MT
07/11	Zymeworks Inc. Announces Step Down of Directors, Effective November 6, 2025	CI
24/25/24	Zymeworks Inc. - Shareholder/Analyst Call
23/25/23	Zymeworks Says ZW191 Shows Anti-Tumor Activity in Phase 1 Trial Initial Data	MT
23/25/23	Zymeworks Inc. Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor- at AACR-NCI-EORTC Conference	CI

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Employees

263

Sector

Biotechnology & Medical Research

Calendar

11/03 - Q4 2025 Earnings Release (Projected)

More about the company